A Maryland federal judge has ruled against Actelion Pharmaceuticals in an antitrust suit, allowing the plaintiffs to proceed with allegations that the company illegally withheld samples needed by generics manufacturers to produce generic versions of its hypertension drug, Tracleer. The judge also certified the case as a class action, which now includes “hundreds” of insurers and self-funded employers. This decision amplifies the legal challenges facing Actelion in the pharmaceutical sector. More details can be found here.